NY-BLACKSTONE
22.2.2021 08:32:07 CET | Business Wire | Press release
Blackstone (NYSE:BX) today announced the appointment of former Centrica CEO, Iain Conn, as a Senior Advisor for energy and sustainability investing. Conn will bring his deep knowledge of the energy sector, climate and sustainability to advise across the firm’s infrastructure and energy businesses.
Blackstone has a long history of acquiring, building and financing renewable and energy efficiency projects. In the past twelve months alone, Blackstone has made meaningful investments including Aypa (formerly known as NRstor) , a battery energy storage pioneer, and Therma Holdings LLC , a leading provider of mechanical, electrical and energy efficiency services, among others; Iain’s appointment will help to further these efforts.
Commenting on the appointment, Sean Klimczak, Global Head of Blackstone Infrastructure Partners said: “Iain’s knowledge of the energy sector will be invaluable as we invest in infrastructure that supports the energy transition toward a more sustainable, decarbonized future. We look forward to benefiting from Iain’s insights, which will better the firm and improve our portfolio for our investors.”
David Foley, Global Head of Blackstone Energy Partners said: “I have known Iain for two decades and I look forward to working with him on private equity investment opportunities, particularly in the energy efficiency and retail electric sectors.”
Iain Conn, former Centrica CEO, said: “I am honored to advise Blackstone. They are already investing in the energy transition and demonstrating leadership in tackling climate change by committing to reduce carbon emissions by 15% across all new investments where the firm controls energy usage. I’m excited to see what the future holds for the firm and the Blackstone portfolio.”
Conn has over 34 years of executive experience in the energy sector, including 29 years with BP plc, latterly as CEO Downstream from 2007-2014. Most recently, from 2015-2020 he was Group Chief Executive of Centrica plc, a Fortune 500 and FTSE 100 energy, services and lower-carbon solutions company. Centrica, which included British Gas, had revenues of £30bn and over 25,000 employees. Conn drove the strategy to reposition the company back to being customer-centric and oriented towards services and solutions to enable the transition to a lower-carbon future.
A chemical engineer by training, Conn possesses a deep understanding of the energy sector built up over a lifetime in the industry, with a track record of strategy formulation and delivery, transactions and major projects, commercial innovation, and material turnarounds of large organizations often in the face of very significant challenges.
Over his career Iain has advised governments on energy and climate policy, and from 2017-2020 Iain Co-Chaired the World Economic Forum System Initiative on the Future of Energy. The System Initiative aimed to enable an effective transition to a more sustainable, affordable, secure and inclusive energy system by accelerating development of effective policies, private-sector action and public-private cooperation.
About Blackstone
Blackstone is one of the world’s leading investment firms. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $619 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com . Follow Blackstone on Twitter @Blackstone.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210221005082/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom